FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2952590523> ?p ?o ?g. }

• W2952590523 abstract "Background Belimumab is a human monoclonal antibody that inhibits soluble B lymphocytes stimulator (BlyS) and represents the only biological drug approved for Systemic Lupus Erythematosus (SLE) (1). Belimumab is effective in reducing disease activity, number of flares and blocking damage progression (2,3). Pooled data derived from clinical trials reported a reduction of anti-dsDNA,analysed by ELISA, anti-cardiolipin (aCL) and anti-Sm and anti-ribosomal protein antibodies (2,4). No data were published on anti-beta2glycoprotein I (GPI) antibodies and other antiENA specificities. Objectives Our aim was to analyse the effect of Belimumab therapy on high avidity anti-dsDNA, aCL, anti-beta2GPI, and other relevant anti-ENA specificities. Methods 50 patients with active SLE (mean SLEDAI-2K score: 7,18;SD:3), with a mean age of 39 years (SD:11) and mean follow-up of 13 years (SD: 7,8) were enrolled. Sera were collected at Belimumab starting (T0) and every 6 months until 24th month. Disease activity index (SLEDAI-2K) was collected at every timepoints. High avidity anti-dsDNA were detected by radioimmunological method, anti-ENA, anti-cardiolipin (aCL), anti-β2 glycoprotein I (anti-β2GPI) were analysed by ELISA. Results At baseline 86% of sera were positive for anti-dsDNA, 50% for anti-ENA, 20% for aCL and 28% for anti-beta2GPI. Anti-dsDNA became negative in 21%, anti-beta2GPI IgG in 33% and aCL IgG in 30% of sera, mostly at T6. Among anti-ENA, 6/10 (60%) anti-ribosomal and 3/17 (17.6%) anti-Sm positive sera became negative. A significant decrease of anti-dsDNA and anti-beta2GPI IgM titers were observed at all timepoints. IgG aCL titre showed significant decrease only at T18. Anti-ribosomal showed a significant titre decrease at T6 and T12, with seroconversion to negative at T18. Anti-Sm titre significantly dropped down at T6, then remained stable during time. A significant correlation between anti-dsDNA and anti-ribosomal titre, and between SLEDAI ratio (SLEDAI value/SLEDAI T0) and anti-ribosomal titer ratio (value/value T0) were found. Conclusion Belimumab treatment induced a significant reduction of SLE-specific autoantibodies titre and IgM anti-beta2GPI. Anti-ribosomal titre decrease correlates with anti-dsDNA titre and improvement of disease activity. References [1] Stohl W, et al. Nat. Biotechnol. 2012; 30: 69-77. [2] Ginzler EM, Wallace et al. J Rheumatol 2014; 41:300-9. [3] Iaccarino et al. Arthritis care Res 2017; 69: 115-123. [4] Stohl W, et al. Arthritis Rheum 2012; 7: 2328-37. Disclosure of Interests Ilaria Cavazzana: None declared, Rajesh Kumar: None declared, Salvatore Panaro: None declared, Chiara Pozzari: None declared, Roberta Ottaviani: None declared, Micaela Fredi: None declared, Silvia Piantoni: None declared, Laura Andreoli: None declared, Angela Tincani Consultant for: UCB, Pfizer, Abbvie, BMS, Sanofi, Roche, GSK, AlphaSigma, Lillly, Jannsen, Cellgene, Novartis, Franco Franceschini: None declared" @default.
• W2952590523 created "2019-06-27" @default.
• W2952590523 creator A5011545464 @default.
• W2952590523 creator A5013868891 @default.
• W2952590523 creator A5021292232 @default.
• W2952590523 creator A5028369292 @default.
• W2952590523 creator A5040088026 @default.
• W2952590523 creator A5046889639 @default.
• W2952590523 creator A5054047592 @default.
• W2952590523 creator A5061119590 @default.
• W2952590523 creator A5073791739 @default.
• W2952590523 creator A5079447134 @default.
• W2952590523 date "2019-06-01" @default.
• W2952590523 modified "2023-09-28" @default.
• W2952590523 title "AB0481 AUTOANTIBODIES’ TITRE MODULATION BY ANTI-BLYS TREATMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS" @default.
• W2952590523 doi "https://doi.org/10.1136/annrheumdis-2019-eular.2613" @default.
• W2952590523 hasPublicationYear "2019" @default.
• W2952590523 type Work @default.
• W2952590523 sameAs 2952590523 @default.
• W2952590523 citedByCount "0" @default.
• W2952590523 crossrefType "proceedings-article" @default.
• W2952590523 hasAuthorship W2952590523A5011545464 @default.
• W2952590523 hasAuthorship W2952590523A5013868891 @default.
• W2952590523 hasAuthorship W2952590523A5021292232 @default.
• W2952590523 hasAuthorship W2952590523A5028369292 @default.
• W2952590523 hasAuthorship W2952590523A5040088026 @default.
• W2952590523 hasAuthorship W2952590523A5046889639 @default.
• W2952590523 hasAuthorship W2952590523A5054047592 @default.
• W2952590523 hasAuthorship W2952590523A5061119590 @default.
• W2952590523 hasAuthorship W2952590523A5073791739 @default.
• W2952590523 hasAuthorship W2952590523A5079447134 @default.
• W2952590523 hasBestOaLocation W29525905231 @default.
• W2952590523 hasConcept C126322002 @default.
• W2952590523 hasConcept C159654299 @default.
• W2952590523 hasConcept C163764329 @default.
• W2952590523 hasConcept C170286685 @default.
• W2952590523 hasConcept C179223381 @default.
• W2952590523 hasConcept C203014093 @default.
• W2952590523 hasConcept C2775915377 @default.
• W2952590523 hasConcept C2776912625 @default.
• W2952590523 hasConcept C2778453870 @default.
• W2952590523 hasConcept C2779134260 @default.
• W2952590523 hasConcept C2780380361 @default.
• W2952590523 hasConcept C2781205201 @default.
• W2952590523 hasConcept C71924100 @default.
• W2952590523 hasConcept C90924648 @default.
• W2952590523 hasConceptScore W2952590523C126322002 @default.
• W2952590523 hasConceptScore W2952590523C159654299 @default.
• W2952590523 hasConceptScore W2952590523C163764329 @default.
• W2952590523 hasConceptScore W2952590523C170286685 @default.
• W2952590523 hasConceptScore W2952590523C179223381 @default.
• W2952590523 hasConceptScore W2952590523C203014093 @default.
• W2952590523 hasConceptScore W2952590523C2775915377 @default.
• W2952590523 hasConceptScore W2952590523C2776912625 @default.
• W2952590523 hasConceptScore W2952590523C2778453870 @default.
• W2952590523 hasConceptScore W2952590523C2779134260 @default.
• W2952590523 hasConceptScore W2952590523C2780380361 @default.
• W2952590523 hasConceptScore W2952590523C2781205201 @default.
• W2952590523 hasConceptScore W2952590523C71924100 @default.
• W2952590523 hasConceptScore W2952590523C90924648 @default.
• W2952590523 hasLocation W29525905231 @default.
• W2952590523 hasOpenAccess W2952590523 @default.
• W2952590523 hasPrimaryLocation W29525905231 @default.
• W2952590523 hasRelatedWork W190726545 @default.
• W2952590523 hasRelatedWork W192937535 @default.
• W2952590523 hasRelatedWork W1983943138 @default.
• W2952590523 hasRelatedWork W2010061727 @default.
• W2952590523 hasRelatedWork W2013145504 @default.
• W2952590523 hasRelatedWork W2124290467 @default.
• W2952590523 hasRelatedWork W2361375798 @default.
• W2952590523 hasRelatedWork W2369335503 @default.
• W2952590523 hasRelatedWork W2415121269 @default.
• W2952590523 hasRelatedWork W2519989553 @default.
• W2952590523 hasRelatedWork W2523653129 @default.
• W2952590523 hasRelatedWork W2726694794 @default.
• W2952590523 hasRelatedWork W2761083010 @default.
• W2952590523 hasRelatedWork W2915391158 @default.
• W2952590523 hasRelatedWork W2953263693 @default.
• W2952590523 hasRelatedWork W3001014778 @default.
• W2952590523 hasRelatedWork W3030060809 @default.
• W2952590523 hasRelatedWork W3165069507 @default.
• W2952590523 hasRelatedWork W3165602618 @default.
• W2952590523 hasRelatedWork W3031054138 @default.
• W2952590523 isParatext "false" @default.
• W2952590523 isRetracted "false" @default.
• W2952590523 magId "2952590523" @default.
• W2952590523 workType "article" @default.